Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended					12 Months Ended
	Feb. 09, 2024 shares	Feb. 08, 2024 shares	Dec. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jan. 31, 2024	Oct. 31, 2023 USD ($) Director $ / shares shares	Sep. 30, 2023 $ / shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares	Nov. 30, 2024 USD ($)	Aug. 31, 2020 USD ($)
Subsidiary Sale Of Stock [Line Items]
Preferred stock, shares authorized			5,000,000					5,000,000	5,000,000
Common stock, shares authorized			150,000,000					150,000,000	150,000,000
Preferred stock, shares issued			0					0	0
Preferred stock, shares outstanding			0					0	0
Listing qualifications of the Nasdaq stock market, description							In September 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company, as the bid price for its common stock had closed below $1.00 per share for the last 30 consecutive business days, it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day period, or until March 25, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard would be met once the closing bid price of the Company’s common stock was at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period.
Reverse stock split ratio	0.0833	0.0833			0.0833
Reverse stock split description	All outstanding stock options and restricted stock units presented have been adjusted to reflect the 1-for-12 Reverse Stock Split.							In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024.
Common stock shares outstanding due to reverse stock split	5,500,000	65,800,000
Number of shares issued in connection with reverse stock split	0
Total proceeds | $								$ 2,030	$ 4,546
Warrant outstanding			814,000					814,000
Warrant exercised			0					0
Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock
Subsidiary Sale Of Stock [Line Items]
Proceeds received from transaction | $						$ 15,200
Number of directors, right to designate in company board | Director						2
Percentage of outstanding common stock						29.90%
Percentage of outstanding common stock subject to stockholder approval						29.90%
Maximum
Subsidiary Sale Of Stock [Line Items]
Closing bid price of stock | $ / shares							$ 1.00
Reverse stock split ratio					0.0588
Minimum
Subsidiary Sale Of Stock [Line Items]
Closing bid price of stock | $ / shares							$ 1.00
Reverse stock split ratio					0.1429
Registered Direct Offering | Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares sold				634,500
Registered Direct Offering | Common Stock and Warrant
Subsidiary Sale Of Stock [Line Items]
Sale of stock, price per share | $ / shares				$ 15.46
Gross proceeds from issuance of common stock and warrant | $				$ 9,800
Registered Direct Offering | Maximum | Warrants to purchase common stock
Subsidiary Sale Of Stock [Line Items]
Number of shares sold				634,500
Private Placement | Gilead Sciences, Inc.
Subsidiary Sale Of Stock [Line Items]
Gross proceeds from issuance of common stock and warrant | $				$ 2,800
Private Placement | Gilead Sciences, Inc. | Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares sold				179,500
Private Placement | Gilead Sciences, Inc. | Common Stock and Warrant
Subsidiary Sale Of Stock [Line Items]
Sale of stock, price per share | $ / shares				$ 15.46
Private Placement | Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares sold			940,499			1,089,472
Sale of stock, price per share | $ / shares			$ 21.37			$ 13.92		$ 21.37
Proceeds received from transaction | $			$ 20,100			$ 15,200
Premium on purchase of common stock | $			5,200			5,900
Fair value of common stock purchased | $			$ 14,900			9,300
Total proceeds | $						9,100
Issuance costs | $						$ 200
Expected equity financing completion period						2024-10
Number of years of standstill provision						3 years
Number of years of lockup provision						2 years
Number of trading days volume considered for weighted average price to calculate premium			30 days
Private Placement | Maximum | Gilead Sciences, Inc. | Warrants to purchase common stock
Subsidiary Sale Of Stock [Line Items]
Number of shares sold				179,500
Private Placement | Maximum | Gilead Sciences, Inc. | Gilead Equity Agreements | Common Stock
Subsidiary Sale Of Stock [Line Items]
Percentage of premium to weighted average price immediately prior to date of purchase			35.00%
Private Placement | Minimum | Gilead Equity Agreements | Common Stock
Subsidiary Sale Of Stock [Line Items]
Potential proceeds from equity financing | $						$ 30,000
June 2024 Registered Direct Offering and June 2024 Private Placement
Subsidiary Sale Of Stock [Line Items]
Warrant exercise price | $ / shares			$ 17.00					$ 17.00
Warrant expiration date								Jun. 18, 2029
2020 At the Market Offerings
Subsidiary Sale Of Stock [Line Items]
Number of shares sold									261,170
Net proceeds from the issuance of common stock through equity plans | $									$ 4,500
2020 At the Market Offerings | Maximum
Subsidiary Sale Of Stock [Line Items]
Initial public offering value of shares authorized | $											$ 100,000
2024 At the Market Offerings
Subsidiary Sale Of Stock [Line Items]
Number of shares sold								152,666
Net proceeds from the issuance of common stock through equity plans | $								$ 2,000
2024 At the Market Offerings | Maximum
Subsidiary Sale Of Stock [Line Items]
Initial public offering value of shares authorized | $										$ 75,000